TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04908826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green (ICG) administration
Description: Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green (ICG) administration
Description: Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green (ICG) administration
Description: Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
Study: NCT06330870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WGS/TME evaluation
Description: WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
Study: NCT05456607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Depression
Description: Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Depression
Description: Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Depression
Description: Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Monitoring
Description: The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
Study: NCT06290180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Face for Mental Heatlh
Description: First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
Study: NCT05713500

Intervention type: OTHER
Intervention: TCI
Description: Temperament and character inventory

Intervention type: OTHER
Intervention: TCI
Description: Temperament and character inventory

Intervention type: OTHER
Intervention: TCI
Description: Temperament and character inventory

Intervention type: OTHER
Intervention: BPI
Description: Brief Pain Inventory

Intervention type: OTHER
Intervention: BPI
Description: Brief Pain Inventory

Intervention type: OTHER
Intervention: CPAQ-8
Description: Chronic Pain Acceptance Questionnaire-8

Intervention type: OTHER
Intervention: CPAQ-8
Description: Chronic Pain Acceptance Questionnaire-8

Intervention type: OTHER
Intervention: SF-MPQ
Description: short-form McGill Pain Questionnaire

Intervention type: OTHER
Intervention: SF-MPQ
Description: short-form McGill Pain Questionnaire

Intervention type: OTHER
Intervention: King's Parkinson's Disease Pain Scale (KPPS)
Description: King's Parkinson's Disease Pain Scale

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale (HAD) questionary
Description: Hospital Anxiety and Depression scale

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale (HAD) questionary
Description: Hospital Anxiety and Depression scale

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression scale (HAD) questionary
Description: Hospital Anxiety and Depression scale

Intervention type: OTHER
Intervention: PCS
Description: Pain Catastrophism Scale

Intervention type: OTHER
Intervention: PCS
Description: Pain Catastrophism Scale

Intervention type: OTHER
Intervention: ORT
Description: Opioid Risk Tool

Intervention type: OTHER
Intervention: ORT
Description: Opioid Risk Tool

Intervention type: OTHER
Intervention: ORT
Description: Opioid Risk Tool

Intervention type: OTHER
Intervention: Social Support Questionnaire (SSQ6)
Description: Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)

Intervention type: OTHER
Intervention: Social Support Questionnaire (SSQ6)
Description: Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)

Intervention type: OTHER
Intervention: IPQ-R
Description: Illness Perception Questionnaire Revised

Intervention type: OTHER
Intervention: WCC-R
Description: Ways of Coping Checklist Revised
Study: NCT05962554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iJobs
Description: iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iJobs
Description: iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
Study: NCT05626595

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Project Group - PRO-ECO Project
Description: The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait List Group - Normal Daily Practice
Description: ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
Study: NCT04983121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
Description: The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
Study: NCT06375408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial alternating electrical stimulation
Description: The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial alternating electrical stimulation
Description: The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
Study: NCT05324735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive placebo (orally ingested) twice a day for 12 weeks.
Study: NCT04465188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encircling scleral buckle surgical procedure
Description: Encircling scleral buckle surgical procedure under general anesthesia
Study: NCT05123937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOBATH technique
Description: In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task training
Description: In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
Study: NCT05292742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib+Trastuzumab+Capecitabine
Description: Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab+Pertuzumab/Trastuzumab
Description: Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
Study: NCT05387902

Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: Patients with high-risk PCI receive mechanical circulatory support with ECMO.
Study: NCT01966081

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: tissue samples from abdominal subcutaneous adipose

Intervention type: OTHER
Group type: OTHER
Intervention: tissue samples from abdominal subcutaneous adipose
Study: NCT05876195

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Keyhole-Limpet Hemocyanin
Description: Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA 51 VG
Description: Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA 51 VG
Description: Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alhydrogel
Description: Alhydrogel is a vaccine adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alhydrogel
Description: Alhydrogel is a vaccine adjuvant
Study: NCT05290181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A support program with pilates exercise and whatsapp text message
Description: Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
Study: NCT06373575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung and inferior vena cava ultrasound guidance
Description: The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol guidance
Description: Fluid removal using conventional protocol including blood pressure and physical examination
Study: NCT05282654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePRO Application
Description: The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
Study: NCT05903365

Intervention type: OTHER
Intervention: Blood sampling
Description: Additional blood samples at J100, M6, M12, M24
Study: NCT06111911

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Diagnostic Kit (Bio Farma)
Description: Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Diagnostic Kit (Bio Farma)
Description: Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
Study: NCT05814458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
Study: NCT06073249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular vagus stimulation
Description: Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tibial Nerve Stimulation
Description: The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
Study: NCT04788680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention 1
Description: Participants receive a beverage with a defined amount of non-nutritive sweetener.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 2
Description: Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 3
Description: Participants receive a beverage with a defined amount of monosaccharide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention 4
Description: Participants receive a beverage with a defined amount of disaccharide.
Study: NCT05111821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Quantification of iron will be performed through Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Quantification of iron will be performed through Magnetic Resonance Imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone treatment
Description: Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
Study: NCT05036603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: diffferent chest physiotherapy methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: diffferent chest physiotherapy methods
Study: NCT04825938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab , Carboplatin, Nab-paclitaxel
Description: Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.